Morgan Tara, Calio Brian, Caraccia Rafael Tua, Segal Daniel, Kim Joshua, Attia Sarah, Desai Neil B, Gahan Jeffery
Department of Urology, Duke University Hospital, Durham, NC 27710, USA.
Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA.
Can J Urol. 2025 Aug 29;32(4):309-315. doi: 10.32604/cju.2025.063408.
Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer.
A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015-2023. Demographic, peri-operative, and post-radiation treatment functional outcomes are reported.
No postoperative or post-EBRT complications were reported for any of the 17 patients who underwent RASP followed by EBRT during a median follow-up time of 12 months. The median time from RASP to EBRT was 9 months. Median prostate size was 135 g (IQR 110-165). 13 (76.5%) patients received a pre-EBRT rectal spacer. Median IPSS score preoperatively improved at 90 days post-RASP (13.5 vs. 2.5; IQR 10.8-15.2), and this benefit was sustained post-EBRT with a median IPSS at 3 vs. 12 months (4 vs. 0; IQR 0-5). There was no statistically significant difference between postoperative IPSS and post-EBRT IPSS at 3 (p = 0.677) or 12 (p = 0.627) months. In all 14 patients with localized disease and PSA data, none had recurrence during the study period.
A subset of patients with clinically significant prostate cancer have marked prostatomegaly and LUTS. We report an alternative treatment approach for patients unwilling to undergo radical prostatectomy. We found robotic simple prostatectomy followed by definitive radiation to be feasible and safe.
对于患有临床显著前列腺癌(PCa)且同时伴有明显下尿路症状(LUTS)的男性,根治性前列腺切除术长期以来一直是首选治疗方法。对于符合这种描述且伴有明显前列腺肿大的男性,我们开展了一项多机构概念验证研究,描述了一种替代途径,即机器人单纯前列腺切除术(RASP)联合外照射放疗(EBRT)用于治疗临床显著前列腺癌。
对2015年至2023年期间在两家机构接受RASP联合EBRT治疗的17例PCa患者进行了回顾性研究。报告了人口统计学、围手术期和放疗后功能结局。
在17例接受RASP联合EBRT治疗的患者中,中位随访时间为12个月,期间未报告任何术后或放疗后并发症。从RASP到EBRT的中位时间为9个月。前列腺中位大小为135 g(四分位间距110 - 165)。13例(76.5%)患者在EBRT前接受了直肠间隔器植入。RASP术后90天,国际前列腺症状评分(IPSS)中位数术前改善(13.5对2.5;四分位间距10.8 - 15.2),放疗后这种益处得以维持,3个月和12个月时IPSS中位数分别为4对0(四分位间距0 - 5)。术后3个月(p = 0.677)和12个月(p = 0.627)时,术后IPSS与放疗后IPSS之间无统计学显著差异。在所有14例有局限性疾病和PSA数据的患者中,研究期间均无复发。
一部分患有临床显著前列腺癌的患者有明显前列腺肿大和LUTS。我们报告了一种针对不愿接受根治性前列腺切除术患者的替代治疗方法。我们发现机器人单纯前列腺切除术联合确定性放疗是可行且安全的。